Labeling Requirements for
Human Prescription Drug and Biological Products
Revision of a currently approved collection
No
Regular
12/23/2021
Requested
Previously Approved
36 Months From Approved
01/31/2022
432,929
541
1,912,106
1,258,907
0
0
The information collection supports
agency regulations governing the content and format of labeling for
human prescription drug and biological products. Respondents to the
collection are sponsors of new drug and biological product
applications.
The information collection
reflects changes and adjustments. We are accounting for burden that
may be associated with requirements found in 21 CFR § 201.328
applicable to the labeling of medical gas containers not previously
included. This results in an overall increase to the collection by
432,388 responses and 653,199 hours annually.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.